Swedish biotech companies Symcel and Colzyx entered a new partnership agreement in order to test Colzyx’s 25 different new collagen VI derived antimicrobial peptides, a first-in-kind new class of molecules characterised by the ability to kill bacteria in different ways. Each peptide will be tested independently or in combination with others.  The analysis will be run with the aid of Symcel’s innovative cell-based assay tool for real-time cellular bioenergetic measurements calScreener™, that enables the calorimetric measurement of heat generated by metobolism and provides the rapid generation of unique information that can’t be acquired through other experimental methods.